Semper Paratus Acquisition (NASDAQ:TVGN) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Semper Paratus Acquisition (NASDAQ:TVGN) in a research report released on Wednesday,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

Semper Paratus Acquisition Stock Performance

Shares of TVGN stock opened at $1.20 on Wednesday. The firm’s 50 day moving average is $1.15 and its 200 day moving average is $1.20. Semper Paratus Acquisition has a 12 month low of $0.26 and a 12 month high of $3.09.

Insider Activity

In related news, CEO Ryan H. Saadi sold 1,438,206 shares of Semper Paratus Acquisition stock in a transaction on Monday, June 9th. The shares were sold at an average price of $1.23, for a total value of $1,768,993.38. Following the transaction, the chief executive officer now owns 116,814,453 shares in the company, valued at $143,681,777.19. This trade represents a 1.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 73.24% of the company’s stock.

Institutional Investors Weigh In On Semper Paratus Acquisition

A number of large investors have recently added to or reduced their stakes in the company. Barclays PLC boosted its stake in Semper Paratus Acquisition by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock worth $48,000 after acquiring an additional 12,847 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Semper Paratus Acquisition by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock valued at $122,000 after purchasing an additional 13,595 shares during the last quarter. JPMorgan Chase & Co. grew its position in Semper Paratus Acquisition by 74.2% during the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock valued at $40,000 after buying an additional 16,695 shares during the period. XTX Topco Ltd bought a new stake in Semper Paratus Acquisition during the fourth quarter valued at approximately $55,000. Finally, Nuveen LLC bought a new stake in Semper Paratus Acquisition during the first quarter valued at approximately $97,000.

Semper Paratus Acquisition Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.